AI English summary of an SEC filing — figures as filed

The company said it completed the Standard BioTools acquisition of SomaLogic and other assets on January 30, 2026, paying $350,000,000 in cash as the purchase price. The amount is subject to customary adjustments.

8-KCompletion of Acquisition or Disposition of AssetsFiled Jan 30, 2026Period of report Jan 30, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said it completed the Standard BioTools acquisition of SomaLogic and other assets on January 30, 2026, paying $350,000,000 in cash as the purchase price. The amount is subject to customary adjustments.
Illumina said it is acquiring SomaLogic, Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools. The business covers aptamer-based and functional proteomics, and excludes the mass cytometry and microfluidics businesses.
The company said the purchase agreement includes royalties payable to Standard BioTools tied to revenue from certain products and services, and up to $75,000,000 in potential milestone payments.
The company said it funded the transaction with cash on hand and will discuss its financial impact on the earnings call scheduled for February 5, 2026.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

SomaLogic Acquisition Completed for $350,000,000 in Cash

The company said it completed the Standard BioTools acquisition of SomaLogic and other assets on January 30, 2026, paying $350,000,000 in cash as the purchase price. The amount is subject to customary adjustments.

Source · Based on the filing body and exhibits

Scope of Acquired Business

Illumina said it is acquiring SomaLogic, Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools. The business covers aptamer-based and functional proteomics, and excludes the mass cytometry and microfluidics businesses.

Source · Based on the filing body and exhibits

Royalties and Up to $75,000,000 in Milestones

The company said the purchase agreement includes royalties payable to Standard BioTools tied to revenue from certain products and services, and up to $75,000,000 in potential milestone payments.

Source · Based on the filing body and exhibits

Funding and Timing of Further Explanation

The company said it funded the transaction with cash on hand and will discuss its financial impact on the earnings call scheduled for February 5, 2026.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.